Get started
Author

Wilfried F. Seifert

The Effects of Tibolone in Older Postmenopausal Women
2008 · Steven R. Cummings, Bruce Ettinger, et al. · New England Journal of Medicine · 469
PDF
Vitamin A deficiency potentiates carbon tetrachloride-induced liver fibrosis in rats
1994 · Wilfried F. Seifert, Anne Bosma, et al. · Hepatology · 97
PDF
Synergism between ethanol and carbon tetrachloride in the generation of liver fibrosis
1988 · Anne Bosma, Adriaan Brouwer, et al. · The Journal of Pathology · 48
Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
2020 · Maria Elisa Mancuso, Aaron Lubetsky, et al. · Journal of Thrombosis and Haemostasis · 47
PDF
Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP
2018 · Sylvia von Mackensen, Jinesh Shah, et al. · Haemophilia · 33
PDF
Endometrial Effects of Tibolone in Elderly, Osteoporotic Women
2008 · Bruce Ettinger, Peter Kenemans, et al. · Obstetrics and Gynecology · 32
Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study
2020 · Gili Kenet, Hervé Chambost, et al. · Thrombosis and Haemostasis · 28
PDF
Intraoperative irradiation delays anastomotic repair in rat colon
1995 · Wilfried F. Seifert, Theo Wobbes, et al. · The American Journal of Surgery · 27
Alcohol in combination with malnutrition causes increased liver fibrosis in rats
1994 · Anne Bosma, Wilfried F. Seifert, et al. · Journal of Hepatology · 23
IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data
2022 · Miguel Escobar, Maria Elisa Mancuso, et al. · Journal of Clinical Medicine · 21
PDF
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
2020 · Maria Elisa Mancuso, Johannes Oldenburg, et al. · Haemophilia · 21
PDF
Catecholamines and endogeneous opioids in ventral tegmental self-stimulation reward
1988 · Leo van Wolfswinkel, Wilfried F. Seifert, et al. · Pharmacology Biochemistry and Behavior · 19
Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
2016 · Toshko J. Lissitchkov, Evgeny Buevich, et al. · Blood Coagulation & Fibrinolysis · 18
Long-term changes in self-stimulation threshold by repeated morphine and naloxone treatment
1985 · Leo van Wolfswinkel, Wilfried F. Seifert, et al. · Life Sciences · 18
Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP
2020 · Julie Curtin, Elena Santagostino, et al. · Thrombosis Research · 13
PDF
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
2020 · Guenter Auerswald, Claudia Djambas Khayat, et al. · Journal of Blood Medicine · 10
PDF
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study)
2015 · Aleksander Skotnicki, Toshko J. Lissitchkov, et al. · Thrombosis Research · 10
Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review
2024 · Cihan Ay, Mariasanta Napolitano, et al. · Haemophilia · 9
PDF
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
2024 · Richard Lemons, Michael Wang, et al. · TH Open · 8
PDF
An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
2020 · Toshko Lissitchkov, Anna Klukowska, et al. · Journal of Blood Medicine · 6
PDF
Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
2023 · Ingrid Pabinger, Toshko Lissitchkov, et al. · Research and Practice in Thrombosis and Haemostasis · 5
PDF
Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study
2020 · Brigitte Pan-Petesch, Azusa Nagao, et al. · Thrombosis Research · 5
PDF
Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A
2025 · Johnny Mahlangu, Maria Elisa Mancuso, et al. · Haemophilia · 4
PDF
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program
2023 · Hans‐Juergen Laws, Katsuyuki Fukutake, et al. · European Journal Of Haematology · 4
PDF
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients
2021 · Claudia Djambas Khayat, Genadi Iosava, et al. · Journal of Blood Medicine · 3
PDF
Works count: 25
Citation count: 978
H-index: 14
I10-index: 17
Year
Topic
Type